drugset / Trial / NCT02896231
First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001
NaSingle-groupOpen-labelTreatment
Summary
This phase I, first-in-human dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary antitumor activity of PLB1001.
Timeline
- Start
- 2016-04
- Primary completion
- 2019-10
- Completion
- 2019-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vebreltinib | Small molecule | 50 mg | — |
| Subject | Vebreltinib | Small molecule | 100 mg | — |
| Subject | Vebreltinib | Small molecule | 150 mg | — |
| Subject | Vebreltinib | Small molecule | 200 mg | — |
| Subject | Vebreltinib | Small molecule | 275 mg | — |